dulaglutide
AssetProtein or enzymeAlso LY2189265
GLP-1 receptor agonist that enhances glucose-dependent insulin secretion.
- Stage
- Approved
- Modality
- Protein or enzyme
- Target
- Insulin/IGF-1 signalling
- Indications
- 12
- Trials
- 66
- Developers
- 2
Indications
12Cardiovascular disease
Approvedaccessdata.fda.gov7 Oct 2026
Cardiovascular events
Approvedema.europa.eu7 Oct 2026
Diabetes
Approvedema.europa.eu7 Oct 2026
9 more
- Targets and what it contains2
- Owner and partners2
- Trials66
- Evidence for its targets3
- Competitors12
- Aging relevance1
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 10 sources